Tag: Loss of Proteostasis

Scientists have found a pathway that regulates protein aggregation, a cause of several age-related neurodegenerative diseases. United by abnormal protein aggregation Most neurodegenerative diseases are age-related, and many of them are similar in other ways. For instance, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and Alzheimer’s disease have all been linked to abnormal protein aggregation [1],...

Researchers publishing in Nature Aging have discovered how Alzheimer's-related protein aggregates are also related to senescent cells and osteoporosis. Beyond the brain Loss of ProteostasisThe loss of proteostasis is the failure of the protein-building machinery of the cell and the accumulation of misfolded proteins, which is one of the root causes of age-related diseases, including...

In Aging Cell, researchers have explored how transcription factor EB (TFEB) promotes proteostasis in a common aging model. Maintaining protein function Loss of ProteostasisThe loss of proteostasis is the failure of the protein-building machinery of the cell and the accumulation of misfolded proteins, which is one of the root causes of age-related diseases, including Alzheimer's...

Research published in Aging Cell has revealed that a nematode species commonly used for aging research lives much longer on an alternate-day fasting regimen, but only when it is administered in middle age and only when the worms are consuming an animal-based protein source. Deciding what to restrict and when Dietary restriction practices have been...

With an in-depth examination tool in hand, researchers publishing in Aging have done a preliminary examination of the muscle protein differences between younger and older people and how older people's proteins change with exercise. The power to take a close look This paper begins with a discussion of proteomics, the science of analyzing what proteins...

A pair of neurologists have published a review in Cell discussing the current state of Alzheimer's therapies, including drugs in early development, treatments in clinical trials, and therapies that are prescribed today. The -mab drugs Monoclonal antibodies, drugs whose names end in -mab, have become the go-to approach for pharma companies seeking to develop anti-Alzheimer's...